AJP - Regulatory, Integrative and Comparative Physiology, Vol 255, Issue 6 1064-R1068, Copyright © 1988 by American Physiological Society

ARTICLES

Cardiovascular, renal, and endocrine responses to intravenous endothelin in conscious dogs

K. L. Goetz, B. C. Wang, J. B. Madwed, J. L. Zhu and R. J. Leadley Jr
Division of Experimental Medicine, St. Luke's Hospital and Foundation, Kansas City, Missouri 64111-9000.

Endothelin is a recently discovered vasoconstrictor peptide that is synthesized in certain vascular endothelial cells. We have identified the cardiovascular, renal, and hormonal responses that can be elicited in conscious dogs by intravenous administration of endothelin at rates of 10 and 30 ng.kg-1.min-1 for 60 min (0.24 and 0.72 nmol.kg-1/1-h infusion). Each dose of endothelin increased total peripheral resistance, arterial pressure, and left atrial pressure and decreased heart rate and cardiac output. Hematocrit increased by 4.8% (NS) and 22.9% (P less than 0.01) in response to the lower and higher infusion rates, respectively. Urinary sodium excretion, urine osmolality, and osmolar clearance decreased and free water clearance increased. The lower dose of endothelin decreased plasma norepinephrine and increased plasma atriopeptin. The higher dose increased plasma levels of vasopressin, renin, aldosterone, norepinephrine, epinephrine, and atriopeptin. The higher infusion rate of the peptide caused one or more brief vomiting episodes in four of five dogs. Although it is not yet known whether endothelin is a circulating hormone, it is clear that this peptide is capable of causing profound cardiovascular, renal, and endocrine alterations in conscious dogs. The possible relevance of these observations to physiological processes and to pathological conditions such as hypertension remains to be established.

This article has been cited by other articles:

				S. D. Stocker, J. C. Schiltz, and A. F. Sved Acute increases in arterial blood pressure do not reduce plasma vasopressin levels stimulated by angiotensin II or hyperosmolality in rats Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2004; 287(1): R127 - R137. [Abstract] [Full Text] [PDF]

				A. A. Elmarakby, P. Morsing, and D. M. Pollock Regulation of Cardiovascular Signaling by Kinins and Products of Similar Converting-Enzyme Systems: Enalapril attenuates endothelin-1-induced hypertension via increased kinin survival Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H1899 - H1903. [Abstract] [Full Text] [PDF]

				N. L. Kanagy, B. R. Walker, and L. D. Nelin Role of Endothelin in Intermittent Hypoxia-Induced Hypertension Hypertension, February 1, 2001; 37(2): 511 - 515. [Abstract] [Full Text] [PDF]

				S. Davies Amniotic fluid embolus: a review of the literature Can J Anesth, January 1, 2001; 48(1): 88 - 98. [Abstract] [Full Text] [PDF]

				G. G. Nussdorfer, G. P. Rossi, L. K. Malendowicz, and G. Mazzocchi Autocrine-Paracrine Endothelin System in the Physiology and Pathology of Steroid-Secreting Tissues Pharmacol. Rev., September 1, 1999; 51(3): 403 - 438. [Abstract] [Full Text] [PDF]

				T. Ikeda, H. Ohta, M. Okada, N. Kawai, R. Nakao, P. K. S. Siegl, T. Kobayashi, S. Maeda, T. Miyauchi, and M. Nishikibe Pathophysiological Roles of Endothelin-1 in Dahl Salt-Sensitive Hypertension Hypertension, September 1, 1999; 34(3): 514 - 519. [Abstract] [Full Text] [PDF]

				H. Berthold, K. Munter, A. Just, H. R. Kirchheim, and H. Ehmke Stimulation of the Renin-Angiotensin System by Endothelin Subtype A Receptor Blockade in Conscious Dogs Hypertension, June 1, 1999; 33(6): 1420 - 1424. [Abstract] [Full Text] [PDF]

				Y. Hiruma, A. Inoue, A. Shiohama, E. Otsuka, S. Hirose, A. Yamaguchi, and H. Hagiwara Endothelins inhibit the mineralization of osteoblastic MC3T3-E1 cells through the A-type endothelin receptor Am J Physiol Regulatory Integrative Comp Physiol, October 1, 1998; 275(4): R1099 - R1105. [Abstract] [Full Text] [PDF]

				G. P. Rossi, E. Zilli, A. C. Pessina, K. A.H. Kaasjager, H. A. Koomans, and T. J. Rabelink Renal Effects of Endothelin-1 in Essential Hypertension • Response Hypertension, February 1, 1998; 31(2): 721 - 722. [Full Text]

				G. S. Potter, R. J. Johnson, and G. D. Fink Role of Endothelin in Hypertension of Experimental Chronic Renal Failure Hypertension, December 1, 1997; 30(6): 1578 - 1584. [Abstract] [Full Text]

				T. Hiramatsu, Y. Imai, Y. Takanashi, S. Hoshino, M. Yashima, S. A. Tanaka, D. Chang, and M. Nakazawa Time Course of Endothelin-1 and Nitrate Anion Levels After Cardiopulmonary Bypass in Congenital Heart Defects Ann. Thorac. Surg., March 1, 1997; 63(3): 648 - 652. [Abstract] [Full Text]

				T. Hiramatsu, J. M. Forbess, T. Miura, S. J. Roth, M. A. Cioffi, Mat, and J. E. Mayer Jr Effects of Endothelin-1 and L-Arginine After Cold Ischemia in Lamb Hearts Ann. Thorac. Surg., January 1, 1996; 61(1): 36 - 40. [Abstract] [Full Text]

				C. E. Whitworth, M. M. Veniant, J. D. Firth, A. D. Cumming, and J. J. Mullins Endothelin in the Kidney in Malignant Phase Hypertension Hypertension, December 1, 1995; 26(6): 925 - 931. [Abstract] [Full Text]

				T. Hiramatsu, J. Forbess, T. Miura, S. J. Roth, M. A. Cioffi MAT, and J. E. Mayer Jr Effects of Endothelin-1 and Endothelin-A Receptor Antagonist on Recovery After Hypothermic Cardioplegic Ischemia in Neonatal Lamb Hearts Circulation, November 1, 1995; 92(9): 400 - 404. [Abstract] [Full Text]

				E. R. Levin Endothelins N. Engl. J. Med., August 10, 1995; 333(6): 356 - 363. [Full Text] [PDF]

				K. A. H. Kaasjager, H. A. Koomans, and T. J. Rabelink Effectiveness of Enalapril Versus Nifedipine to Antagonize Blood Pressure and the Renal Response to Endothelin in Humans Hypertension, April 1, 1995; 25(4): 620 - 625. [Abstract] [Full Text]